Cullinan Therapeutics, Inc. (CGEM) Sets Q4 Data Milestones in Autoimmune and Oncology
Cullinan Therapeutics will present multi-dose regimen data for CLN-978 in SLE, RA and Sjögren’s in December, velinotamig SLE data at ACR in November, and updated CLN-049 AML Phase 1 data in December, with plans to initiate a potentially registrational Phase 2 for CLN-049.Material DetailsContext by…